CDSCO Cancels Registration Certificate of G3 Medical Systems for Import of Allergan Cosmetics
New Delhi:The Central Drugs Standard Control Organisation (CDSCO) has confirmed the cancellation of Registration Certificate (RC) No. RC/COS-002850, previously issued to G3 Medical Systems Pvt. Ltd., Chennai, for the import of cosmetics manufactured by Allergan Sales LLC, USA. According to CDSCO, the company had applied through the SUGAM portal (application no. COS/PostAppr/2025/38350 dated May 21, 2025) seeking voluntary surrender of the registration. Acting on the request, the regulatory authority has officially cancelled the RC with immediate effect. The notice read, The certificate, originally granted on December 14, 2021, was valid until December 13, 2026. With this cancellation, G3 Medical Systems will no longer be authorized to import the said cosmetics into India. As part of the regulatory process, CDSCO has also circulated the order to all Zonal, Sub-Zonal, and Port Offices to ensure compliance and prevent import of the products under the surrendered registration. To view the official notice, click the link below:
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!